Neo Ivy Capital Management acquired a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 26,516 shares of the company's stock, valued at approximately $1,545,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of PROCEPT BioRobotics by 9.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,779 shares of the company's stock valued at $527,000 after purchasing an additional 723 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of PROCEPT BioRobotics by 189.2% during the 4th quarter. Sei Investments Co. now owns 95,315 shares of the company's stock valued at $7,675,000 after purchasing an additional 62,359 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of PROCEPT BioRobotics by 6.1% during the 4th quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock valued at $413,907,000 after purchasing an additional 297,075 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of PROCEPT BioRobotics by 7,021.1% during the first quarter. GAMMA Investing LLC now owns 6,409 shares of the company's stock worth $373,000 after buying an additional 6,319 shares in the last quarter. Finally, Bessemer Group Inc. grew its holdings in shares of PROCEPT BioRobotics by 50.7% during the first quarter. Bessemer Group Inc. now owns 10,900 shares of the company's stock worth $635,000 after buying an additional 3,665 shares in the last quarter. Institutional investors own 89.46% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently issued reports on the company. Oppenheimer assumed coverage on PROCEPT BioRobotics in a report on Monday, July 7th. They set a "market perform" rating for the company. Bank of America decreased their price objective on PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Friday, April 25th. Truist Financial decreased their price objective on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. Morgan Stanley decreased their price objective on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating for the company in a report on Tuesday, July 15th. Finally, Wall Street Zen downgraded PROCEPT BioRobotics from a "hold" rating to a "sell" rating in a report on Saturday, July 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, PROCEPT BioRobotics has a consensus rating of "Moderate Buy" and a consensus price target of $84.13.
Read Our Latest Stock Report on PROCEPT BioRobotics
PROCEPT BioRobotics Stock Performance
PRCT traded down $0.14 during trading on Tuesday, hitting $53.95. The stock had a trading volume of 344,776 shares, compared to its average volume of 959,013. The company has a 50 day moving average price of $58.86 and a 200-day moving average price of $60.56. The firm has a market cap of $2.98 billion, a price-to-earnings ratio of -31.64 and a beta of 1.07. PROCEPT BioRobotics Corporation has a one year low of $47.04 and a one year high of $103.81. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.95 and a quick ratio of 7.75.
Insiders Place Their Bets
In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 25,000 shares of PROCEPT BioRobotics stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $61.49, for a total value of $1,537,250.00. Following the completion of the transaction, the director directly owned 14,363 shares of the company's stock, valued at $883,180.87. The trade was a 63.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders sold 100,000 shares of company stock valued at $6,271,250. 17.40% of the stock is owned by insiders.
PROCEPT BioRobotics Profile
(
Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Featured Articles
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
